Volume | 32,381,456 |
|
|||||
News | - | ||||||
Day High | 1.19 | Low High |
|||||
Day Low | 0.7531 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.772 | 0.7531 | 1.19 | 0.95 | 0.8074 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
79,724 | 32,381,456 | US$ 1.02 | US$ 33,151,273 | - | 0.75 - 140.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:59 | formt | 124 | US$ 0.99 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
24.39M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.34 | 2.45 | 0.75 | 1.20 | 9,813,705 | -1.35 | -57.69% |
1 Month | 11.13 | 13.25 | 0.75 | 9.01 | 29,375,238 | -10.14 | -91.11% |
3 Months | 24.84 | 26.20 | 0.75 | 8.16 | 26,514,039 | -23.85 | -96.01% |
6 Months | 31.73 | 32.49 | 0.75 | 8.28 | 12,387,907 | -30.74 | -96.88% |
1 Year | 67.01 | 140.00 | 0.75 | 12.52 | 6,530,846 | -66.02 | -98.52% |
3 Years | 275.00 | 987.00 | 0.75 | 173.44 | 4,525,707 | -274.01 | -99.64% |
5 Years | 275.00 | 987.00 | 0.75 | 173.44 | 4,525,707 | -274.01 | -99.64% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |